Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | AGXT | P21549 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19831965 | 0.84 | TSHR (0.39) | TSHRIDO1ALDH1A1AGXTLMNA | |
| SCHEMBL18229656 | 0.83 | ALDH1A1 (0.38) | TSHRIDO1ALDH1A1AGXTLMNA | |
| SCHEMBL18229698 | 0.83 | TSHR (0.38) | TSHRIDO1ALDH1A1AGXTLMNA | |
| SCHEMBL17974797 | 0.80 | TSHR (0.41) | TSHRIDO1ALDH1A1TRPA1AGXT | |
| SCHEMBL19829640 | 0.77 | TSHR (0.39) | TSHRIDO1ALDH1A1AGXTLMNA | |
| SCHEMBL18229704 | 0.75 | CA1 (0.39) | TSHRALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL18229700 | 0.75 | IDO1 (0.33) | TSHRIDO1ALDH1A1AGXTLMNA | |
| SCHEMBL19829058 | 0.75 | TSHR (0.36) | TSHRIDO1ALDH1A1AGXTTDP1 | |
| SCHEMBL17963379 | 0.74 | TSHR (0.43) | TSHRIDO1ALDH1A1AGXTLMNA | |
| SCHEMBL10780111 | 0.74 | SGMS2 (0.44) | TSHRIDO1ALDH1A1AGXTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597401-B2 | Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180134724-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OMACETAXINE AND CEPHALOTAXINE DERIVATIVES THEREOF | CURIA BUFFALO R&D, LLC | 2018-05-17 | — | — | US | disclosed |
| US-20180134724-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OMACETAXINE AND CEPHALOTAXINE DERIVATIVES THEREOF | CURIA BUFFALO R&D, LLC | 2018-05-17 | — | — | US | disclosed |
| WO-2016182850-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OMACETAXINE AND CEPHALOTAXINE DERIVATIVES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597401-B2 | Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof | MAOB, MAOA, NISCH | TSHR 3247/4885IDO1 199/4885ALDH1A1 418/4885 |
| US-20180134724-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF OMACETAXINE AND CEPHALOTAXINE DERIVATIVES THEREOF | MAOB, MAOA, NISCH | TSHR 3247/4885IDO1 199/4885ALDH1A1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.